Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered PRN2246 in Healthy Volunteers

Next Previous
Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered PRN2246 in Healthy Volunteers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolebrutinib (Primary)
  • Indications Autoimmune disorders; CNS disorders; Inflammation; Multiple sclerosis
  • Focus Adverse reactions; First in man

Most Recent Events

  • 01 Mar 2019 According to a Principia Biopharma media release, results from this study were presented at the American Consortium for Therapy and Research in Multiple Sclerosis (ACTRIMS) annual meeting.
  • 01 Mar 2019 Results presented in the Principia Biopharma media release.
  • 16 Oct 2018 According to a Principia Biopharma media release, the company intends to present the results of this Phase I clinical trial at a future scientific conference.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top